Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
about
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspectiveLeflunomide: a drug with a potential beyond rheumatologyArthritis and the Risk of Falling Into Poverty: A Survival Analysis Using Australian Data.Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.Interleukin-1 receptor antagonist intervenes in signaling between different types of synoviocytes in rats with adjuvant arthritis.Special features of health services and register based trials - experiences from a randomized trial of childbirth classes.Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolAnti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.The personal and national costs of lost labour force participation due to arthritis: an economic study.Exploring the diversity of conceptualizations of work (dis)ability: a scoping review of published definitions.Predictive factors of work disability in rheumatoid arthritis: a systematic literature reviewCombination treatment strategies in early rheumatoid arthritis.EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US.Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysisSick leave and work disability in patients with early arthritisEstimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE studyImproving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs.Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registryAscendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.Work in inflammatory and degenerative joint diseases.Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study.Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis.Chronic health conditions and poverty: a cross-sectional study using a multidimensional poverty measure.Access to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system.Evolution of treatment for rheumatoid arthritis.Does disease activity at start of biologic therapy influence work-loss in RA patients?Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register.Quality of life and costs for different treatment strategies for rheumatoid arthritis.Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.Labour force participation and the influence of having arthritis on financial status.Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis.Prognostic factors for long-term work disability due to musculoskeletal disorders.Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.Psychiatric and cardiovascular comorbidities as causes of long-term work disability among individuals with recent-onset rheumatoid arthritis.The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study.Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
P2860
Q24816803-9898DA34-797E-485C-BCD1-7D5868285A35Q26770099-258E301C-04B5-4AEC-9C21-B94D8687EF95Q28294236-C2372AE2-3CB6-4871-9B58-227F3F16532CQ30994490-F8BC4775-BB2F-4530-9419-FCE93F00C4EFQ31019080-6ED7F9A1-81E3-4D43-850C-B41323F0B263Q33229888-3283B9C0-4BA0-41CC-A240-DFE7B16BBC62Q33343093-C9A6D904-6C55-4603-BB22-2421B6373739Q34117111-5ABE6C8E-26E2-4DDC-9221-6B8A7E6EBC9CQ34244715-4539BB9F-A2C3-4630-AA12-F2005639C589Q34604509-F220B097-F107-4635-B964-E7F148009311Q34864506-D15565AC-230D-463A-B102-F5852A984C60Q35553588-A929A45F-6C61-4351-93E7-C0505E6A00E1Q35556077-FA847CCA-CC2A-4BB9-8D47-3EC1AA063298Q35638360-4B57BA50-BEDC-4F80-BC7C-DE274CE05406Q35638583-2BC43101-4EEB-4F00-AB2A-E7FF5DE93A40Q35754388-878E0F2B-1512-430B-B341-B53A1748542DQ36166120-C220206C-0AF9-4F90-A359-03279C13FC40Q36183792-EEF34DA7-74DA-40D3-9A70-18E759C84418Q36243390-845E83E8-D54D-466F-890E-D49C684A4407Q36668191-4E3C849C-C0C6-4686-8025-6EC221B06166Q36893038-06C0C53A-7DCB-412C-8910-F1D3723529AAQ36923056-67A95175-2ECA-4C1D-A45C-3BBB0126AAF3Q37101040-208EC11D-7252-42AF-B787-58BD7C062646Q37172804-DFFAAD62-CF43-4D9A-8596-9FAC77AAE471Q37206972-99EC129C-3DA9-435E-87A4-D748596E357CQ37352879-A6B28E9B-FE7A-4D73-8A1B-B5CE6B7B5E1BQ37552303-77037EA5-9CEC-4A67-9322-E2CA5298B68BQ38065767-7D3C3E94-CE37-4E48-AA3E-467C511AD67FQ38410704-E478293F-DBDB-4BB4-9B29-6B6709EFF171Q39888893-60D720CF-69F2-4CFC-8412-6421527D32F6Q40360229-D86EB740-3A58-4564-8F12-2891933CA958Q40401339-87EBE06C-920D-42C9-A32A-6D8B0D5F8D36Q40455661-9D8E0692-3751-412A-8377-18ADB19E3DE9Q41513290-02BF1954-F90E-4337-BD43-33AE83BBFF7EQ44373707-1CD6B607-5706-4997-834B-8F8DB5B132BAQ44476316-9264C2D1-CF8F-40AE-8055-FE88CA3F090BQ48891747-A0E6DB8B-FAF7-4108-807B-68A26EFB4688Q50616014-ED044441-3290-4F20-97B6-7F2A946BC197Q50945018-F71BD00A-AA79-49F5-8448-368DFBF3E2EDQ51129676-9CBF7AC2-430D-407E-B195-AE7262429574
P2860
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Impact of initial aggressive d ...... ear randomized followup trial.
@en
type
label
Impact of initial aggressive d ...... ear randomized followup trial.
@en
prefLabel
Impact of initial aggressive d ...... ear randomized followup trial.
@en
P2093
P2860
P356
P1476
Impact of initial aggressive d ...... year randomized followup trial
@en
P2093
Hannu Kautiainen
Harri Blåfield
Heikki Julkunen
Kaisa Vuori
Kari Puolakka
Leena Paimela
Marjatta Leirisalo-Repo
Markku Hakala
Markku Korpela
Pekka Hannonen
P2860
P356
10.1002/ART.11436
P577
2004-01-01T00:00:00Z